NVAX Novavax Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NVAX

Price (delayed)

$9.2

Market cap

$1.51B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.54

Enterprise value

$1.58B

?
Relative Growth: Rel. Growth: 3
Relative Strength: Rel. Strength: 58
Relative Valuation: Rel. Valuation: 19
Relative Profitability: Rel. Profitability: 22

Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. As of 2020, it has an ongoing Phase III ...

Highlights
NVAX's quick ratio is up by 29% since the previous quarter and by 28% year-on-year
Novavax's net income has plunged by 120% from the previous quarter and by 118% YoY
Novavax's EPS has shrunk by 120% QoQ and by 118% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.novavax.com/
Peers: SRPT AGEN EBS BCRX

Key stats

What are the main financial stats of NVAX

NVAX stock price

How has the Novavax stock price performed over time
Intraday
-0.11%
1 week
6.11%
1 month
1.55%
1 year
30.87%
YTD
36.9%
QTD
13.02%

Financial performance

How have Novavax's revenue and profit performed over time
Revenue
$596.34M
Gross profit
$506.72M
Operating income
-$78.15M
Net income
-$87.84M
Gross margin
85%
Net margin
-14.7%
The operating margin has dropped by 140% year-on-year and by 133% since the previous quarter
Novavax's net margin has shrunk by 139% YoY and by 138% QoQ
Novavax's net income has plunged by 120% from the previous quarter and by 118% YoY
Novavax's operating income has plunged by 119% YoY and by 117% from the previous quarter

Price vs fundamentals

How does NVAX's price correlate with its fundamentals

Growth

What is Novavax's growth rate over time

Valuation

What is Novavax stock price valuation
P/E
N/A
P/B
N/A
P/S
2.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.65
Novavax's EPS has shrunk by 120% QoQ and by 118% YoY
Novavax's equity has shrunk by 91% YoY and by 13% QoQ
NVAX's P/S is 80% above its last 4 quarters average of 1.4 but 13% below its 5-year quarterly average of 2.9
The revenue has plunged by 52% YoY and by 47% from the previous quarter

Efficiency

How efficient is Novavax business performance
Novavax's return on sales has shrunk by 127% YoY and by 126% QoQ
NVAX's return on assets has dropped by 125% year-on-year and by 121% since the previous quarter
The ROIC has plunged by 114% from the previous quarter and by 104% YoY

Dividends

What is NVAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NVAX.

Financial health

How did Novavax financials performed over time
Novavax's total assets is 12% lower than its total liabilities
NVAX's quick ratio is up by 29% since the previous quarter and by 28% year-on-year
The current ratio has increased by 20% year-on-year and by 16% since the previous quarter
Novavax's equity has shrunk by 91% YoY and by 13% QoQ
NVAX's debt to equity is up by 32% year-on-year but it is down by 4.6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.